Sarepta Therapeutics, Inc. (LON:0L35)

Sarepta Therapeutics Statistics

Total Valuation

LON:0L35 has a market cap or net worth of GBP 1.79 billion. The enterprise value is 2.22 billion.

Market Cap	1.79B
Enterprise Value	2.22B

Important Dates

The next estimated earnings date is Monday, November 3, 2025.

Earnings Date	Nov 3, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	97.71M
Shares Outstanding	n/a
Shares Change (YoY)	-0.99%
Shares Change (QoQ)	+9.51%
Owned by Insiders (%)	5.04%
Owned by Institutions (%)	82.39%
Float	87.65M

Valuation Ratios

PE Ratio	n/a
Forward PE	18.04
PS Ratio	0.99
PB Ratio	1.80
P/TBV Ratio	1.84
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.03, with an EV/FCF ratio of -6.72.

EV / Earnings	-52.38
EV / Sales	1.17
EV / EBITDA	18.03
EV / EBIT	n/a
EV / FCF	-6.72

Financial Position

The company has a current ratio of 2.89, with a Debt / Equity ratio of 1.01.

Current Ratio	2.89
Quick Ratio	1.53
Debt / Equity	1.01
Debt / EBITDA	8.45
Debt / FCF	-3.02
Interest Coverage	-0.05

Financial Efficiency

Return on equity (ROE) is -4.76% and return on invested capital (ROIC) is -0.02%.

Return on Equity (ROE)	-4.76%
Return on Assets (ROA)	-0.02%
Return on Invested Capital (ROIC)	-0.02%
Return on Capital Employed (ROCE)	-0.03%
Revenue Per Employee	1.32M
Profits Per Employee	-30,832
Employee Count	1,372
Asset Turnover	0.70
Inventory Turnover	2.59

Taxes

In the past 12 months, LON:0L35 has paid 24.69 million in taxes.

Income Tax	24.69M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -81.02% in the last 52 weeks. The beta is 0.50, so LON:0L35's price volatility has been lower than the market average.

Beta (5Y)	0.50
52-Week Price Change	-81.02%
50-Day Moving Average	20.31
200-Day Moving Average	48.02
Relative Strength Index (RSI)	62.58
Average Volume (20 Days)	31,999

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.47

Income Statement

In the last 12 months, LON:0L35 had revenue of GBP 1.81 billion and -42.30 million in losses. Loss per share was -0.44.

Revenue	1.81B
Gross Profit	412.49M
Operating Income	-680,267
Pretax Income	-17.61M
Net Income	-42.30M
EBITDA	29.30M
EBIT	-680,267
Loss Per Share	-0.44

Balance Sheet

The company has 584.02 million in cash and 995.80 million in debt, giving a net cash position of -411.78 million.

Cash & Cash Equivalents	584.02M
Total Debt	995.80M
Net Cash	-411.78M
Net Cash Per Share	n/a
Equity (Book Value)	990.76M
Book Value Per Share	10.14
Working Capital	1.27B

Cash Flow

In the last 12 months, operating cash flow was -219.52 million and capital expenditures -110.06 million, giving a free cash flow of -329.58 million.

Operating Cash Flow	-219.52M
Capital Expenditures	-110.06M
Free Cash Flow	-329.58M
FCF Per Share	n/a

Margins

Gross margin is 22.77%, with operating and profit margins of -0.04% and -2.34%.

Gross Margin	22.77%
Operating Margin	-0.04%
Pretax Margin	-0.97%
Profit Margin	-2.34%
EBITDA Margin	1.62%
EBIT Margin	-0.04%
FCF Margin	n/a

Dividends & Yields

LON:0L35 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.99%
Shareholder Yield	0.99%
Earnings Yield	-2.37%
FCF Yield	-18.45%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0L35 has an Altman Z-Score of 2.08 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.08
Piotroski F-Score	1